Premium
Prediction of efficacy of interferon treatment of chronic hepatitis C by multivariate analysis and a new classification
Author(s) -
Kim Soo Ryang,
Hayashi Yoshitake,
Yoon Seitetsu,
Taniguchi Miyuki,
Yang Moo Kwan,
Kim Ke Ih,
Kim Myung Mi,
Saeki Keizo,
Nukata Isao,
Imoto Susumu
Publication year - 1998
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.1998.tb03895.x
Subject(s) - medicine , gastroenterology , liver biopsy , stage (stratigraphy) , fibrosis , interferon , viremia , grading (engineering) , multivariate analysis , hepatitis c , alanine aminotransferase , biopsy , alanine transaminase , chronic hepatitis , alpha interferon , immunology , biology , virus , paleontology , ecology
One hundred and fifteen patients with chronic hepatitis C were administered interferon (IFN) and classed into two groups: (i) complete responders (CR), HCV‐RNA continuously negative 1 year after treatment; and (ii) non‐responders (NR), positive 1 year after treatment. Multivariate analysis comprised eight variables: age, sex, transfusion history, alanine aminotransferase level, viral genotype, level of viremia, type of IFN, and total amount of IFN. The HCV‐RNA level was correlated with complete response (P = 0.0175). Liver biopsy specimens were classified into four grades and stages according to the measure of severity and the extent of fibrosis, respectively. There was no correlation between the efficacy rate and grading. However, in staging there was a difference in the efficacy of IFN between stages 1 or 2, and stage 3 (0.05< P <0.1 and 0.01 < P <0.025, respectively). Of the CR patients, 0% (0/5) were at stage 0 (no fibrosis); 27.5% (22/80) at stage 1 (mild); 42.9% (6/14) at stage 2 (moderate); and 6.3% (1/16) at stage 3 (severe fibrosis). Thus the new classification would be useful in predicting roughly the efficacy of IFN.